SITE DIRECTED PROTEIN ANALYSIS--FUNCTIONAL IMPLICATIONS

Information

  • Research Project
  • 2869542
  • ApplicationId
    2869542
  • Core Project Number
    R44GM057090
  • Full Project Number
    2R44GM057090-02
  • Serial Number
    57090
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/1998 - 27 years ago
  • Project End Date
    4/30/2001 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    5/1/1999 - 26 years ago
  • Budget End Date
    4/30/2000 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/1/1999 - 26 years ago
Organizations

SITE DIRECTED PROTEIN ANALYSIS--FUNCTIONAL IMPLICATIONS

DESCRIPTION: (adapted from applicant's abstract) The overall goal of this SBIR grant proposal is to develop and commercialize our biochemical techniques to produce large quantities of bilogical proteins containing synthetic amino acids at predetermined sites. In Phase I, we established an efficient and robust method for the elaboration of such proteins. In Phase II, we will prepare a set of analogues of key side chain-functionalized amino acids and demonstrate that each of the amino acids can be incorporated efficiently at a single site in a protein of interest. We will make chloramphenicol acetyltransferase analogues using those synthetic amino acids to explore protein function. We will also develop a structurally novel amino acid that can be derivatized post-translationally after incorporation into a single, predetermined site of a protein, and will synthesize novel fluorescent reporter groups and demonstrate their incorporation into that site of the protein and their utility in defining protein conformation. In the latter phase of this program, we will produce mg quantities of each of two DHFR analogues to validate the overall approach. At the conclusion we will have reagents and information necessary to successfully market a robust and efficient means of analyzing the function(s) of specific amino acids in proteins and to produce modified proteins at levels significantly greater than is currently possible. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    ANNOVIS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ASTON
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19014
  • Organization District
    UNITED STATES